Hikma Addresses Advair Issues In US
Responds To All Outstanding Questions In The FDA’s CRL
Hikma has submitted a response to the US FDA addressing all outstanding deficiencies in its application for a generic version of GlaxoSmithKline’s Advair Diskus.
